Podcasts

Subscribe to our Podcasts

Discussing Lupus: Voclosporin-based triple immunosuppressive therapy and new ACR guidelines for lupus nephritis

Steering Committee member Professor Maria Dall’Era, Professor of Medicine and Chief of the Division of Rheumatology at the of University of California, San Francisco, USA, is joined by fellow member Professor Brad Rovin, who is Lee A. Hebert Professor of Nephrology and Medical Director at Ohio State University Clinical Research Management Institute, Columbus, Ohio, on the latest Lupus Forum podcast.

Together, they discuss the efficacy and safety of a voclosporin-based triple immunosuppressive regimen and summarise the latest ACR guidance to screen, treat, and manage lupus nephritis.

Discussing Lupus: Efficacy and safety results of iberdomide in CLE, and SGLT2i vs. DPP4i in both SLE and comorbid type 2 diabetes

Steering Committee member Professor Victoria Werth, who is Chief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Pennsylvania, USA, is joined by fellow member Professor Chi-Chiu Mok, who is Chief of the Division of Rheumatology, Department of Medicine, Tuen Mun Hospital, Hong Kong, on the latest Lupus Forum podcast.

Together, they discuss the efficacy and safety of iberdomide in CLE, as well as the efficacy and safety of SGLT2i vs. DPP4i for the primary prevention of cardiovascular disease and renal events in SLE and comorbid type 2 diabetes.

Discussing Lupus: Defining ANA-associated arthritis and achieving treatment targets

Steering Committee members Professor Ed Vital, who is a Professor in Autoimmune Connective Tissue Diseases and Honorary Consultant Rheumatologist, at Leeds Teaching Hospitals NHS Trust, UK, is joined by Professor Richard Furie, who is Chief of the Division of Rheumatology at the Department of Medicine, Northwell Health, New York, and Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell, and Professor Liz Lightstone, from the Imperial College Healthcare NHS Trust Renal and Transplant Centre, Hammersmith, London, on the latest Lupus Forum podcast.

Together, they discuss defining ANA-associated arthritis and proposing new basket trial groupings, as well as evaluating the achievement of EULAR/ERA-EDTA treatment targets in lupus nephritis and the need for therapy adjustments.

Discussing Lupus: Sequential belimumab and rituximab treatment and CAR T-cell therapy

Steering Committee members Professor Chris Edwards from the University Hospital Southampton NHS Foundation Trust is joined by Professor Victoria Werth, from the Philadelphia Veterans Administration Hospital, Pennsylvania, USA on the latest Lupus Forum podcast.

Together, they discuss the efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with SLE, as well as CD19-CAR T-cell therapy inducing B cell deep tissue depletion!

Discussing Lupus: Flare Prediction and CD163 in Lupus Nephritis

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Doctor Antony Psarras, an NIHR Academic Clinical Lecturer in Rheumatology at the University of Oxford and at the Kennedy Institute of Rheumatology.

Together, they discuss the use of CD163 as a marker for diagnosis and flare in lupus nephritis. They also discuss the impact of discontinuing immunosuppression on the disease, in particular looking at novel research surrounding the predictors of flares, time to withdrawal and long-term outcomes.

July 2024 Monthly Publications Podcast

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Vibeke Strand, Adjunct Clinical Professor at the Division of Immunology and Rheumatology at Stanford University School of Medicine in California. Together, they discuss the efficacy and safety of upadacitinib and elsubrutinib combination and monotherapy, as well as the association of LLDAS with improved outcomes in SLE.